Form 4: Adaptive Biotechnologies Exec Sells Shares Under 10b5-1 Plan

Adaptive Biotechnologies Corp. reports a Form 4 filing detailing stock transactions by Chief People Officer Francis Lo, executed under a pre-arranged trading plan.

Summary

• Francis Lo, Chief People Officer at Adaptive Biotechnologies Corp., reported transactions involving company common stock on April 8, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on September 15, 2025.
• Lo acquired 2,344 shares of common stock at a price of $3.99 per share.
• Lo also disposed of 22,564 shares of common stock at a weighted average price of $15.07, with individual sales ranging from $14.99 to $15.25.
• Following these transactions, Lo beneficially owns 271,154 shares directly and 2,500 shares indirectly through a spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it details insider transactions, the use of a Rule 10b5-1 plan indicates a pre-planned strategy rather than a reaction to new information, balancing acquisition and disposition.

Positives

• The acquisition of 2,344 shares at a lower price point ($3.99) could indicate a belief in future value appreciation by the executive.
• The execution of a Rule 10b5-1 plan demonstrates proactive and compliant insider trading practices, mitigating concerns about market timing.

Negatives

• The disposal of 22,564 shares at a significantly higher price ($15.07 average) indicates a realization of gains by a key executive.
• The substantial sale volume may be interpreted by the market as a signal of reduced confidence or a need for liquidity by the executive.

Risks

• The disposal of a significant number of shares by a key executive could be perceived negatively by the market, potentially impacting share price.
• While executed under a 10b5-1 plan, large sales can still create downward pressure on the stock price due to increased supply.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The transactions are based on a pre-established trading plan.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2025.
• The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.25, inclusive.
• The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

Industry Context

StockSavvy.ai notes that insider transactions, particularly under Rule 10b5-1 plans, are common in the biotechnology sector as executives manage personal portfolios while adhering to regulatory requirements. The specific price points of acquisition and sale may reflect market conditions and individual financial planning.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by an executive as a potential negative signal, though the 10b5-1 plan mitigates this concern to some extent.
• Employees: May observe executive trading patterns as an indicator of company performance or executive confidence.
• Creditors: Unlikely to be directly impacted by this specific insider transaction.

Next Steps

• The reporting person may continue to execute trades under the existing Rule 10b5-1 plan.
• The company may receive requests for further information regarding the specific prices of the disposed shares.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Stock Acquisition, Beneficial Ownership, Executive Compensation, Securities Exchange Act